title: Multiple Endocrine Neoplasia: Genetics and Clinical Management.
abstract: Early diagnosis of multiple endocrine neoplasia (MEN) syndromes is critical for optimal clinical outcomes; before the MEN syndromes can be diagnosed, they must be suspected. Genetic testing for germline alterations in both the MEN type 1 (MEN1) gene and RET proto-oncogene is crucial to identifying those at risk in affected kindreds and directing timely surveillance and surgical therapy to those at greatest risk of potentially life-threatening neoplasia. Pancreatic, thymic, and bronchial neuroendocrine tumors are the leading cause of death in patients with MEN1 and should be aggressively considered by at least biannual computed tomography imaging.
authors.affiliation: Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA. Electronic address: janorton@stanford.edu.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Norton
authors.affiliation: Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA.
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Krampitz
authors.affiliation: Cell Biology Section, Digestive Diseases Branch, National Institute of Arthritis, Diabetes, Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD 20892-2560, USA.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Jensen
mesh_terms: D019468:Disease Management; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006801:Humans; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis* / Q000235:genetics*; D000090063:Proto-Oncogene Mas; D018570:Risk Assessment
keywords: Clinical management; Endocrine neoplasia; Genetics; Multiple endocrine neoplasia